Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AMG 0101

Next Previous
Drug Profile

AMG 0101

Alternative Names: AMG0101; AMG0102; AMG0103; AMS-001; MP 40; MP 41; MP 42; NDON; NF-kappa-B decoy oligo; NF-kappa-B decoy oligonucleotide; NF-kappa-B-Decoy-AnGes-MG; NF-kappa-B-transcription-factor-Decoy-AnGes; NF-kappaB decoy; NF-kB decoy oligo; NF-kD-transcription-factor-Decoy-AnGes; NF-κB decoy oligo DNA; Nuclear-factor-kappa-B-Decoy-AnGes; S-414114; SI-3104

Latest Information Update: 06 Aug 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AnGes MG; Osaka University
  • Developer AnGes; Hosokawa Micron Corporation; Medikit; Morishita Jintan; Nippon Zoki; Osaka University; Shionogi
  • Class Analgesics; Anti-inflammatories; Antipsoriatics; Antirheumatics; Oligonucleotides; Skin disorder therapies
  • Mechanism of Action Genetic transcription modulators; NF-kappa B inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Atopic dermatitis
  • Phase II Back pain
  • Discontinued Inflammatory bowel diseases; Intervertebral disc degeneration; Musculoskeletal disorders; Pain; Periodontal disorders; Psoriasis; Respiratory tract disorders; Spondylosis; Vascular restenosis

Most Recent Events

  • 30 Jul 2025 Updated efficacy and adverse events data from a phase Ib trial in Back pain released by AnGes
  • 28 Dec 2023 No recent reports of development identified for phase-I development in Back-pain in USA (Intraspinal, Injection)
  • 18 Oct 2023 Phase-II clinical trials in Back pain in Japan (Intraspinal)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top